BridgeBio Oncology Therapeutics, Inc. (BBOT) — Insider Trading

AI-Powered SEC Filing Analysis

Latest Insider Trading Filed: 2026-05-12

Key Insights

Pedro Beltran, President and CEO, received a stock option grant of 1,103,837 shares at an exercise price of $7.66, vesting monthly over 4 years starting April 20, 2026, indicating recent equity compensation tied to long-term retention.
This is a routine equity grant with standard vesting provisions, suggesting normal executive compensation practices rather than a signal of significant company performance or strategy changes.
As the CEO and Director, Beltran now holds 1,103,837 shares in derivative form, representing substantial potential future equity ownership that aligns management incentives with shareholder value creation.

Want the newest filings?

This analysis covers the filing from 2026-05-12. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Insider Trading filings

Filed: 2026-05-12

COO & Principal Financial Officer Elmelech Idan received a substantial stock option grant of 758,222 shares at $7.66 exercise price, vesting monthly over 4 years starting April 20, 2026, indicating confidence in his strategic role and long-term commitment expectations.
The option grant timing (transaction date 05/10/2026, filing date 05/12/2026) and vesting schedule aligned with April 20, 2026 start date suggest this is a standard equity compensation arrangement rather than opportunistic insider trading.
No direct common stock purchases or dispositions are reported in this filing, only the derivative security (option grant), which is typical for executive compensation but provides limited insight into Idan's personal conviction in the stock's near-term direction.

Filed: 2026-03-26

Peter F. Lebowitz, a director of BridgeBio Oncology Therapeutics, Inc. (BBOT), has been granted a stock option to acquire 63,350 shares of the company's common stock. The option has a strike price of $8.72 and vests over 36 months, indicating a long-term commitment to the company.
This insider acquisition suggests that Lebowitz has a positive outlook on the company's future prospects and is willing to tie his personal wealth to the performance of BBOT's stock.
The timing of the option grant, in March 2026, is notable as it comes amid a period of potential market uncertainty. Insider transactions around this time could provide insights into management's views on the company's near-term outlook.

Filed: 2026-03-12

The reporting person, Ben Yong, was granted 46,670 restricted stock units (RSUs) and a stock option for 210,000 shares, both vesting over 4 years, indicating an increase in their equity stake in the company.
The grant of the RSUs and stock option suggests the company is providing additional long-term incentives to retain and motivate the Chief Medical and Development Officer.
The insider transaction suggests the company's leadership believes in the long-term growth prospects of the business and is aligning their interests with shareholders.

Filed: 2026-03-12

The reporting person, Pedro Beltran, was granted 46,670 restricted stock units (RSUs) by BridgeBio Oncology Therapeutics, Inc. (BBOT), which vest over a 4-year period.
Beltran was also granted a stock option to purchase 210,000 shares of BBOT common stock, with a 10-year term and a vesting schedule of 1/48th per month starting January 1, 2026.
The reported transactions indicate that Beltran, who holds the title of Chief Scientific Officer, is being incentivized and retained through equity-based compensation.

Filed: 2026-03-12

Uneek Mehra, the Chief Financial Officer, has been granted 23,330 restricted stock units (RSUs) that vest over 4 years, indicating the company's commitment to retaining and incentivizing key leadership.
Mehra has also been granted 105,000 stock options with a strike price of $10.19, further aligning her interests with those of shareholders.
The insider activity suggests the company is making efforts to motivate and retain its executive team, which could be positive for future performance.

Other reports for BridgeBio Oncology Therapeutics, Inc.

Current Report Quarterly Report Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.